Programme(s) to which this project applies:
|☑ MPhil/PhD||☒ MRes[Med]||☒ URIS|
Nasopharyngeal carcinoma (NPC) highly associated with Epstein-Barr virus (EBV), is endemic in Hong Kong. Patients with NPC are all uniformly treated with high-dose radiation therapy, with additional (concurrent chemoradiation) or adjunct chemotherapy for advanced diseases. Unfortunately, about 30% of patients still relapse within 5 years despite such radical intensive treatment. Therefore, resistance to chemotherapy and radiotherapy remains a major problem for successful management of NPC. A hallmark of undifferentiated NPC is a marked and substantial infiltration of immune cells into the TME, however, no immune checkpoint inhibitors have been approved for NPC. In this project, we shall evaluate the importance of biological or natural products in the combination with current therapies, e.g. cisplatin or immune-checkpoint inhibitors, in restoring sensitivity to apoptosis and potentially modulating the immune-microenvironment of NPC.
For more information or to express interest for this project, please email the supervisor or the specified contact point in the project description. Interested candidates are advised to enclose with your email:
Information on the research programme, funding support and admission documentations could be referenced online at the Research Postgraduate Admissions website.
General admission enquiries should be directed to firstname.lastname@example.org.